Objectives: To understand the dynamic viral evolution observed during failure on raltegravir-containing regimens, we studied the genotypic and phenotypic patterns of resistance to raltegravir and the residual replication capacity (rRC) of HIV-1 variants selected in vivo.
Introduction
Integration of the HIV-1 genome into the host chromosomes, a crucial step of the HIV-1 replication cycle, is driven by the virusspecific integrase enzyme. HIV-1 integration is a multistep process including: (i) formation of the pre-integration complex (which allows entry of viral genomes into the cell nucleus); (ii) 3 0 -endonucleolytic processing (which prepares both ends of the proviral DNA for integration); and (iii) final strand transfer (which joins the viral and nicked chromosomal DNA). 1 These steps are crucial for HIV-1 replication, and therefore the viral integrase has been considered an interesting target for antiretroviral therapy. Recently, the first strand-transfer inhibitor raltegravir was licensed. Raltegravir selectively binds with high affinity to a conserved region of the enzyme known as the catalytic core domain. 2, 3 Raltegravir has provided a novel option to treat HIV-1-infected subjects, including those who are failing previous anti-HIV-1 regimens. 4 -6 Viral variants resistant to raltegravir have been observed in patients failing raltegravir-containing regimens. In particular, several amino acid substitutions within or proximal to the catalytic core domain have been described in these variants, including Y143R/C, N155H and Q148K/R/H. 5, 7, 8 Although these findings have suggested a low genetic barrier for this compound, 9 ,10 a complex dynamic of resistance mutations has been documented in vivo in subsequent studies. In fact, when raltegravir is # The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org J Antimicrob Chemother 2010; 65: 425 -433 doi:10.1093/jac/dkp477 Advance publication 7 January 2010 maintained despite virological failure, a stepwise accumulation of primary and secondary mutations in the viral genome, as commonly reported in the past for other drug classes, 11 is observed only in a minority of patients. Otherwise, the mutation pattern of resistant viral variants has been shown to evolve under continuous drug pressure, and it is not uncommon for viral variants bearing distinct combinations of resistance mutations to be totally substituted by others. 10, 12, 13 In this context, a precise understanding of the virological role of HIV-1 integrase sequence evolution under pharmacological pressure in vivo is crucial not only to clarify the determinants of viral resistance, but also to optimize the management of this important antiviral drug. Unfortunately, comparative genotypic and phenotypic data using samples obtained ex vivo from patients failing raltegravir-containing regimens that could explain the heterogeneous spectra of variants observed in vivo are limited. Moreover, the effects of combinations of resistance mutations on the HIV-1 replication capacity (RC) are poorly described at present. In the study described here, the phenotypic profile to raltegravir and the RC of resistant HIV-1 variants selected in vivo were evaluated using recombinant viral vectors and sequential HIV-1 integrase sequences from 11 infected subjects failing raltegravir-based regimens.
Patients and methods
This research was conducted in accordance with the Declaration of Helsinki and national and institutional standards, and was approved by the San Raffaele ethics committee. Eleven HIV-infected subjects failing on raltegravir-based regimens were included.
Genotypic analyses and virological and immunological evaluation
Patients were prospectively monitored at baseline and every 4 -8 weeks for clinical, virological and immunological parameters including HIV-1 viraemia (Versant HIV-q RNA 3.0 Assay, Bayer, USA) and CD4þ T cell counts. Adherence to therapy was evaluated for each patient by using a selfreported questionnaire. Resistance to antiretroviral drugs (ARVs) was estimated according to the Stanford database report (http://hivdb.stanford .edu), and baseline viral tropism was evaluated using the Trofile TM co-receptor assay (Monogram; http://www.trofileassay.com). Resistance to raltegravir was evaluated according to the Stanford database report and published ex vivo phenotypic data [see Table S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)]. 9,10,12 -14 Amplification and cloning of the HIV-1 integrase gene Viral RNA was extracted using a QIAamp viral RNA mini kit (Qiagen, Valencia, CA, USA). Only one sample at a time was processed, and clinical samples and all amplification steps were conducted with a limiting dilution strategy to minimize artificial recombination events. The integrase region spanning codons 1 -288 was targeted, employing nested RT-PCR using primers Int1F (5 0 -CAT GGG TAC CAG CAC ACA CAA AGG-3 0 ) and Int1R (5 0 -CCA TGT TCT AAT CCT CAT CCT GTC-3 0 ) in the first PCR round and primers Int2F (5 0 -GGA ATT GGA GGA AAT GAA CAA GTA GAT-3 0 ) and Int2R (5 0 -GCC ACA CAA TCA TCA CCT GCC ATC-3 0 ) in the second PCR round. The first RT-PCR was performed in 50 mL using the SuperScript TM III Platinum High-Fidelity One-Step qRT-PCR System (Invitrogen, Carlsbad, CA, USA) with the following thermal profile: 30 min at 508C and 10 min at 958C for 1 cycle, 1 min at 958C, 1 min at 528C and 1 min and 10 s at 728C for 50 cycles, followed by 10 min at 728C. The second PCR was performed in 100 mL using PCR SuperMix High Fidelity (Invitrogen) with the same thermal profile. 15 Before molecular cloning, a 10 mL aliquot of the amplified product was run on a 10% polyacrylamide gel to screen for the appropriately sized band (850 bp). Amplified products were initially cloned into pNL(AD8)Dint BB2 proviral vector (see below) to test viral susceptibility to raltegravir. Baseline-derived samples were then subcloned into the pNL(AD8)Dint BB1 vectors (see below) by EcoRI-AgeI digestion to test viral RC. Individual clones were then sequenced using an ABI PRISM 3100 Genetic Analyzer w (Applied Biosystems, Foster City, CA, USA).
Phenotypic assays
Phenotypic assays were planned and optimized to evaluate the level of resistance ex vivo of specific viral sequences directly amplified from patients' samples and to assess the RC of recombinant clones. These assays were based on the generation of specifically modified vectors: pNL(AD8)Dint BB1mut and pNL(AD8)Dint BB2.
All experiments were performed on freshly purified CD4þ T cells obtained from healthy blood donors as previously described. 16 In brief, peripheral blood mononuclear cells were obtained by Histopaque-Ficoll gradient centrifugation and then activated with phytohaemagglutinin (0.5 mg/mL) and interleukin-2 (100 U/mL) for 3 days. Then, CD4þ T cells were purified by magnetic beads (Miltenyi) and immediately used to evaluate drug activity or viral RC. All of the experiments were performed in triplicate after obtaining informed consent from all healthy blood donors. PCR-directed mutagenesis was used to obtain a deletion of the 1 -301 integrase region-encoding sequence and to introduce two restriction sites (XbaI and SmaI) for cloning ex vivo genes (Figure 1a ) into the pNL(AD8) CCR5 tropic backbone. Two separate PCR amplifications were performed on the pNL(AD8) vector by using the following primer pairs: AgeFw and EcoXbaRw (preSMA amplicon 1) or SmaXbaFw and VifEcoRw (preSMA amplicon2). The preSMA amplicon1 and pNL(AD8) vector were then digested with AgeI/EcoRI and purified by gel extraction using a QIAEX II Gel Extraction Kit (Qiagen). After overnight ligation of purified digested amplicon and vector, transformation of competent cells (Omnimax cells; Invitrogen) by the heat shock technique was performed. Bacterial colonies were grown in 5 mL of Luria-Bertani medium, and plasmids were extracted by use of a Miniprep kit (Promega), according to the manufacturer's instructions. Correct cloning was verified by sequencing of the plasmid, and the vector was called pNL(AD8)Dint intermediate vector. The preSMA amplicon 2 and pNL(AD8)Dint intermediate vector were then double digested with EcoRI/XbaI and purified by gel extraction using a QIAEX II Gel Extraction Kit. After overnight ligation of purified amplicon and vector, competent cells were transformed by the heat shock technique. Bacterial colonies were grown, and extracted plasmids were verified by sequencing.
(ii) Generation of pNL(AD8)Dint BB1 and pNL(AD8)Dint BB2 backbones Two distinct recognition tags were inserted into the sequence of the previously generated integrase-deleted vector. This allowed the construction of two distinct HIV-1 backbones, pNL(AD8)Dint BB1 and pNL(AD8)Dint Canducci et al.
BB2, which can be generated after transfection of identical recombinant viruses with a specific molecular signature that allowed us to identify each variant in co-infection experiments. Two distinct artificial linkers (linkerBB1 and linkerBB2) were cloned in a natural Xho restriction site in the nef gene of the pNL(AD8) (R5-tropic) proviral backbone. The two linkers with Xho-compatible sticky ends were generated by denaturation and slow re-annealing of the following oligonucleotide pairs: LinkerBB1f (TCG ATC TGC AGC CGG) and LinkerBB1r (TCG ACC GGC TGC AGA); and LinkerBB2f (TCG AAG TGC CTC TGG) and LinkerBB2r (TCG ACC AGA GGC ACT). Each linker was then ligated by using T4 DNA ligase (Promega, Madison, WI, USA) into Xho-digested pNL(AD8) vectors. A 2 ml aliquot of the ligation reaction mixture was used to transform competent cells (Omnimax cells; Invitrogen) by the heat shock technique. Correct cloning of the insert was verified by sequencing with the primers BBseqF3 (GAT GGC CTG CTG TAA GGG AAA G) and BBseqR3 (TTA GCT GCT GTA TTG CTA CTT GTG ATT G). The original Xho site is lost when the linkers are ligated into the vector. Correct cloning of the linkers allowed reconstitution of the HIV-1 nef gene frame, with the addition of the following amino acid sequence in both backbones sets in the translated Nef protein: serine -alanine-alanine-arginine. The two linkers in fact differ in Phenotype of HIV-1 integrase resistance 427 JAC nucleotide sequence, but code for the same amino acids since homologous synonymous codons were used. Two additional silent mutations were generated on the BB1 vector genome by means of site-directed mutagenesis with a proofreading enzyme (pfuUltra II Fusion HS DNA polymerase, Stratagene) and the following primer pairs: BB1mutRFw (AAA CAT GGA GCA ATT ACA AGT AGC AAT ACA GC) and BB1mutRRw (GCT GTA TTG CTA CTT GTA ATT GCT CCA TGT TT); and BB1mutFFw (TGC TGT AAG GGA AAG GAT GAG ACG AGC TGA G) and BB1mutFRw (CTC AGC TCG TCT CAT CCT TTC CCT TAC AGC A).
Multiple cycle competition assay
Variation of RC within each patient was evaluated by using a novel multiple cycle competition assay that allowed us to estimate RC by co-infecting the same well with the fully replicating baseline variant [cloned into the pNL(AD8)Dint BB1 vector] and each of the subsequent timepoint-derived recombinant viruses [cloned into the pNL(AD8)Dint BB2 vector] (Figure 1b) . The relative RC of each resistant variant was thus evaluated by quantifying the relative proportion of baseline and subsequent timepoint-derived viruses during several days of co-infection. Infectious molecular clones were generated by transfection into 293T kidney epithelial cells by Fugene 6 (Roche Diagnostics, Inc., Indianapolis, IN, USA) according to the manufacturer's instructions. Culture supernatants were harvested after 48 h. Virus titre was determined by infecting CD4þ cells seeded in 96-microwell plates and infected with serial dilution of culture supernatants. After 8 days of infection, p24 production (AAlto bioreagents) was used to determine virus titre according to the Karber formula. Infections were performed in 96-microwell plates previously seeded with CD4þ T cells (100 000 cells/well), with a 0.001 multiplicity of infection of both a BB1 infectious clone (baseline clone) and a BB2 infectious clone (containing the resistant variants selected). Each virus mixture was incubated for 4 h at 378C in 5% CO 2 . Subsequently cells were washed twice with PBS and seeded in 200 mL of RPMI supplemented with 10% fetal calf serum and interleukin-2 (100 U/mL). Viral RNA was purified from 10 mL of co-culture supernatants at 3, 4, 5, 6 and 7 days post-infection, by using the MdX automatic extractor (Qiagen) and then re-suspended in 70 mL of elution buffer (Tris-HCl pH 8.0). To determine the exact proportion of each virus variant at each time point, two distinct one-step real-time RT-PCRs were conducted with an ABI PRISM 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA). Two separate standard curves were generated by serial dilution of the pNL(AD8)DintBB1 or pNL(AD8)DintBB2 backbone. The following primer pairs and probes specific for each backbone were used: BB2Fw (GGC CTG CTG TAA GGG AAA GA), BB2Rw (GTT AGC TGC TGT ATT GCT ACT TGT GA) and BB2MGBprobe (Vic-TCT CGA AGT GCC TCT GG); or BB1Rw (GTT AGC TGC TGT ATT GCT ACT TGT AA), BB1Fw (GGC CTG CTG TAA GGG AAA GG) and BB1MGBprobe (FAM-TCT GCA GCC GGT CGA). The two primer pairs are almost identical and differ only in single silent nucleotide polymorphisms near the 3 0 end of both the forward and the reverse primers in order to increase amplification specificity for each backbone set. Amplification efficiency was identical for both RTPCRs (data not shown). Quantitative RT-PCR was performed in duplicate for each sample. The reactions contained 2.5 mL of extracted RNA, 200 nM of each primer, 160 nM MGB probe, 5 mL of iscript one-step RT-PCR mix (BioRad) and water to a final volume of 10 mL.
Estimation of viral RC variation
Estimation of relative fitness was calculated from the average of the results of 3 -6 independent growth competition assays (at different competitor ratios). For each co-infection the relative fitness representing the residual RC (rRC) of the escape variant compared with the baseline sample was calculated in the following way: (i) the 'partial' rRC of each variant was calculated between each timepoint during the co-infection experiment with the following formula: rRCi¼Wi/wi where Wi is the proportion of the variant at the later timepoint and wi the proportion of the same variant at the immediately preceding timepoint; (ii) the average rRC was calculated between partial rRC values obtained within the same experiment.
Estimation of HIV-1 susceptibility to raltegravir
Drug susceptibility was evaluated as previously described with minor modifications. 16, 17 In brief, for each analysis CD4þ T cells were collectively infected with 100 TCID 50 (50% tissue culture infectious dose) of each recombinant virus. After 4 -5 h of infection, cells were washed with PBS twice and seeded in 96-well plates (100000 cells/well) in duplicate. Ten raltegravir serial dilutions were then added to the cultures. After 5 days, the supernatant was recovered and viral RNA was quantified by RT-PCR as described above.
Results
All patients reported 100% adherence, apart from patients 1, 2 and 11 (82.5, 70 and 60%, respectively). All patients were maintained on raltegravir treatment except for patient 5 (see below).
All recombinant viruses generated from baseline samples were fully susceptible to raltegravir, with a raltegravir 50% inhibitory concentration (IC 50 ) of between 0.5 and 1.5 nM, even for patient 7, whose HIV-1 plasma load consistently remained above 200 copies/mL during the observation period (Figure 2 ). Virological failure whilst on raltegravir was always associated with failure to all drugs present in the regimen (data not shown), as evaluated by genotype and tropism at the time of failure. In all patients except patient 7, failure was associated with selection of mutations in positions 143, 148 or 155 (Table 1) . Unlike mutations at position 143 (Y143S/K/R) identified both alone and in combination, mutations at position 155 and 148 were always found in combination (Table 1) .
Fold change resistance increase (FCRI) of escape mutants varied from 10 to .700 compared with baseline ( Figure 3) . Interestingly, two patients (patients 5 and 6) had a rapid rebound in HIV-1 viraemia between week 4 and 12 due to selection of rare mutations at position 143 (Y143K and Y143S). Interestingly, although these variants conferred limited resistance to raltegravir (20 and 10 FCRI compared with baseline, respectively; Figure 3 ) and had no substantive impact on viral RC, they paved the way to major mutations (N155H þV151I and Q148R þE138K) selected at later points in time and associated with an important FCRI. In six out of the nine patients who were followed-up for at least 48 weeks, the viral population continued to change when the selective pressure of the compound was maintained, especially in those patients who selected a pattern different from Q148H þG140S at the time of failure. Indeed, viral variants associated with the highest FCRI (.300) were all carrying this combination alone or associated with other primary or secondary mutations, except for patient 4 in whom a complex genotype was selected (L74M, T97A, E138A, Y143C) at week 64 associated with 300 FCRI. Otherwise, mutations at position 143 (Y143C/G/R/K) had a variable impact on raltegravir resistance, possibly modulated by the presence of compensatory mutations at position 72, 74 or 97, which, except in the case of Y143R and Y143K, were invariably co-selected. Of note, the level of resistance to raltegravir Phenotype of HIV-1 integrase resistance 429 JAC displayed by variants with the N155H mutation was between 42-and .400-fold change resistance (Figure 3 ), suggesting that this substitution is highly influenced by the viral genetic background or by other primary mutations. Viral competition assays were used to evaluate the relative RC of each resistant variant and were performed by competing samples at each timepoint with the baseline-derived recombinant viruses in those patients where an evolving genotype was observed (patients 3, 4, 5 and 6). In validation experiments, the RC of competing identical baseline samples was not affected by the difference of linkers, and the specificity of the real-time reaction was able to selectively and linearly amplify the corresponding variant even if present at a 1:10 000 ratio in the mixed population (data not shown). Resistance-associated mutations caused a limited reduction of viral RC (from 0 to 66% fold change reduction from baseline) with a general tendency to restore RC to the baseline levels during follow-up. Importantly, mutations selected at week 4 and 8 at position 143 (Y143K or Y143S), showing an increase in IC 50 to raltegravir, had no negative impact on viral RC. The net effect on RC variations due to mutations observed in positions 143 and 155 was heterogeneous (from none to 66%). The G140S þQ148H combination caused a 27% reduction of viral RC in almost all variants that selected this pattern. This combination was observed in some cases early after treatment failure or, in other cases, when other variants bearing different patterns were substituted by viruses with these two resistance mutations.
Discussion
The phenotypic counterpart of integrase gene evolution in 11 triple-class failing patients was evaluated in this study. A wide range of resistance levels to raltegravir was observed in clinical samples; these are the result of combinations of primary and secondary mutations and are responsible for the heterogeneous values of raltegravir IC 50 . Since the variation of RC was modest in almost all patients where a dynamic evolution in the quasispecies was observed, the driving force of selection that most probably explains the substitutions described in the viral populations during continuous drug pressure is the level of raltegravir resistance. Interestingly, two distinct profiles were observed: (i) variants rapidly reaching high levels of resistance (most of them exhibiting a G140SþQ148H pattern) (Figure 3 ; patients 2 and 10); and (ii) a progressive increase in raltegravir resistance observed in those patients that maintained raltegravir in their regimens after failure, in the majority of cases not associated with accumulation of mutations in the same population, but with replacement by novel variants bearing different combinations. In the latter group, the replacement was normally paralleled by an increase of resistance levels (Figure 3) , as we observed in those patients who were maintained under raltegravir treatment and for whom follow-up was available (patients 3, 4, 5, 6 and 8).
Notably, the progressive increase in raltegravir resistance (group 2) was not only associated with viral evolution within the same pattern, but also with complete shifts to other signature substitutions or to combination of more than one pattern (Table 1) . Novel mutations with limited FCRI such as Y143S or Y143K (not present at baseline) rapidly selected at failure were Table 1 . OV72I þT206S
OT97Aþ125A þV151IþN155H
WT, wild type, i.e. no primary or secondary mutations were observed as compared with NL4-3 sequence. Each distinct variant identified is indicated by a filled triangle. X indicates that the genotype was the same as at the previous timepoint.
Canducci et al. Phenotype of HIV-1 integrase resistance soon replaced by already known combinations with higher FCRI. In patients 6 and 9, the initial selection of G140SþY143R (þN155H in patient 9) probably facilitated the evolution toward the G140Sþ Q148H pathway that was rapidly identified at later timepoints in both patients (Table 1) .
This phenomenon contradicts previous observations, which suggested that the main patterns were mutually exclusive. 13, 14 In our patients, mutations in positions 143 and 155 or in positions 143, 155 and 148 co-existed and were usually associated with modest RC reduction and a synergistic effect on viral FCRI to raltegravir.
Any mutation that we identified in position 155, 143 or 148 caused resistance to raltegravir, independently of the many different amino acids that were selected. Moreover, the level of resistance was not only linked to the amino acid found in those positions, but was highly modulated by the combination with secondary (compensatory) mutations and also by the background integrase sequence present in each patient at baseline. This could also explain some minor discrepancies observed in the level of resistance conferred by identical combinations (such as Y143RþT97A between patients 3 and 4). Moreover, the selected populations showed only a modestly reduced RC compared with baseline viruses.
Our observations apparently contrast with the idea that the integrase enzyme has a very limited spectrum of variability, especially in its catalytic core domain due to its highly regulated and at the same time crucial role in the virus life cycle. 18 Phenotypic analysis of ex vivo resistant variants with fully replicating viruses had not been performed before by competition assays, and in vitro analysis by single cycle assays or by measuring the enzymatic activity of purified integrase enzymes, although reproducible, may not describe the real consequence of resistance mutations on replicating viruses. 7, 19 Moreover, the data obtained by site-directed mutagenesis using laboratory-adapted viruses cannot take into consideration the genetic background of viruses circulating in infected patients. Thus, we optimized a novel method that could be used to test virus RC ex vivo by competition, allowing full replication to occur in a homogeneous population of human purified CD4þ T lymphocytes. We must, however, stress that the majority of resistant viruses that were identified in patients' plasma were already carrying a combination of primary and secondary mutations at the time of failure, with the exception of those variants whose RC was not affected (Y143S/K/R). Previous data obtained in vitro (by sitedirected mutagenesis or by inducing escape mutants) showed that primary or secondary mutations are associated, individually, with deleterious effects on RC. 7, 20 This is in agreement with our findings, since we can hypothesize that mutations at positions 155 or 148, or secondary mutations, if acquired alone in a minority virus population, would hardly allow viral replication to reach the level of detection in peripheral blood until compensatory mutations occur to restore enzyme function. Moreover, even if failure on raltegravir-containing regimens can occur with selection of only one mutation in position 143, which requires in the majority of cases a single transversion from the wild-type genotype and suggests a low genetic barrier for this drug, in a significant proportion of patients escape was observed only with the combination of at least two mutations, thus requiring several transitions or transversions. 21 The reason may indeed reside in several factors, including (i) inter-patient variation of drug concentrations, which we could not measure in our study and that may vary depending on the drugs present in the therapeutic regimen of each patient and their adherence to highly active antiretroviral therapy (HAART) 22 -25 or (ii) the effect on enzyme function of secondary resistance mutations present in distinct circulating virus variants. This could also be the reason why combinations, and not isolated signature mutations, replaced previously replicating resistant patterns during therapy maintenance.
The G140Sþ Q148H combination was associated with the highest level of resistance in all patients; this combination seems to represent the endpoint of the viral evolution under raltegravir selective pressure. In fact, patients whose early failure was linked with this pattern maintained it for the follow-up period. In those patients where failure was associated with the other signature mutations, early variants were substituted or evolved to other patterns, especially towards the Q148H þG140S combination. This could be an important point, since the continuous evolution of integrase to increase resistance to raltegravir can have important consequences on the clinical management of HIV-1-infected patients. Indeed, while mutations in positions 155 and 148 have been associated with cross-resistance to elvitegravir, the Y143R/C/K/H variants may have a limited effect on elvitegravir susceptibility (even if phenotypic testing of all the variants that we identify in patients will clarify to what extent this in vitro observation can also be applied to ex vivo samples). 18 Thus an early genotypic evaluation of patients failing a raltegravir-based regimen may allow a prompt identification of those patients (20 -30% of all raltegravir-failing subjects) who select viruses with mutations in position 143. In fact, an immediate interruption of raltegravir treatment would prevent virus evolution toward cross-resistant variants that will emerge in a significant proportion of these patients due to their higher FCRI.
In some patients followed in the present study, the viral load, the RC and the level of resistance to raltegravir seem not to be in agreement as theoretically expected. In fact, when mutations conferring higher FCRI and rRC were selected, a parallel increase in viral load was not observed in some cases [patient 6 (weeks 24 and 48), and patient 8 (week 64)]. Although this aspect deserves further investigation, the level of intra-patient viral replication may be influenced by multiple factors. Moreover when viraemia reaches the level observed before raltegravir introduction (as observed also with mutations conferring poor FCRI), such as in patients 3 (week 24) and 5 (week 12), further increases in resistance and RC may have an immediate impact on the composition of the viral population, but only a less predictable effect on the virological and immunological parameters observed in each patient in vivo. Finally, it should be stressed that the present study has addressed one of the therapeutic targets of the antiretroviral therapy in vitro, and the evolution of HIV-1 resistance to the other antiretroviral drugs could have influenced the overall viral fitness in vivo, this being particularly true in triple-class failing patients such as those described in this study.
Overall, the present study documents two distinct patterns of viral evolution in patients receiving raltegravir, driving the variants towards either a fast or a progressive increase in resistance to the compounds. These results may have implications not only on the evaluation of genotypic results, but also on the correct clinical use of the antiviral drug.
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